Corvus Pharmaceuticals (CRVS) Receivables - Net (2022 - 2026)

Corvus Pharmaceuticals' Receivables - Net history runs 5 years deep, the most recent figure standing at $43000.0 for Q1 2026.

• In Q1 2026, Receivables - Net fell 45.57% year-over-year to $43000.0; the TTM figure through Mar 2026 stood at $43000.0 (down 45.57% YoY), while the FY2025 annual figure was $37000.0, down 50.67% from the prior year.
• Receivables - Net for Q1 2026 stood at $43000.0, up from $37000.0 in the prior quarter.
• The five-year high for Receivables - Net was $588000.0 in Q4 2022, with the low at $11000.0 in Q3 2023.
• The 5-year median for Receivables - Net is $40000.0 (2025), against an average of $92333.3.
• The sharpest annual moves came in 2023 and 2024: Receivables - Net sank 95.58% in 2023, then surged 536.36% in 2024.
• Corvus Pharmaceuticals' Receivables - Net stood at $588000.0 in 2022, then tumbled by 95.58% to $26000.0 in 2023, then surged by 188.46% to $75000.0 in 2024, then sank by 50.67% to $37000.0 in 2025, then increased by 16.22% to $43000.0 in 2026.
• Business Quant data shows CRVS's Receivables - Net at $43000.0 in Q1 2026, $37000.0 in Q4 2025, and $32000.0 in Q3 2025.